FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012430170> ?p ?o ?g. }

• W2012430170 endingPage "27388" @default.
• W2012430170 startingPage "27383" @default.
• W2012430170 abstract "The endothelial nitric-oxide synthase (eNOS) is activated by transient increases in intracellular Ca2+ elicited by stimulation of diverse receptors, including bradykinin B2 receptors on endothelial cells. eNOS and B2 receptors are targeted to specialized signal-transducing domains in the plasma membrane termed plasmalemmal caveolae. Targeting to caveolae facilitates eNOS activation following receptor stimulation, but in resting cells, eNOS is tonically inhibited by its interactions with caveolin, the scaffolding protein in caveolae. We used a quantitative approach exploiting immunofluorescence microscopy to investigate regulation of the subcellular distribution of eNOS in endothelial cells by bradykinin and Ca2+. In resting cells, most of the eNOS is localized at the cell membrane. However, within 5 min following addition of bradykinin, nearly all the eNOS translocates to structures in the cell cytosol; following more protracted incubations with bradykinin, most of the cytosolic enzyme subsequently translocates back to the cell membrane. The bradykinin-induced internalization of eNOS is completely abrogated by the intracellular Ca2+ chelator BAPTA; conversely, Ca2+-mobilizing drugs and agonists promote eNOS translocation. These results establish that eNOS targeting to the membrane is labile and is subject to receptor-regulated Ca2+-dependent reversible translocation, providing another point for regulation of NO-dependent signaling in the vascular endothelium. The endothelial nitric-oxide synthase (eNOS) is activated by transient increases in intracellular Ca2+ elicited by stimulation of diverse receptors, including bradykinin B2 receptors on endothelial cells. eNOS and B2 receptors are targeted to specialized signal-transducing domains in the plasma membrane termed plasmalemmal caveolae. Targeting to caveolae facilitates eNOS activation following receptor stimulation, but in resting cells, eNOS is tonically inhibited by its interactions with caveolin, the scaffolding protein in caveolae. We used a quantitative approach exploiting immunofluorescence microscopy to investigate regulation of the subcellular distribution of eNOS in endothelial cells by bradykinin and Ca2+. In resting cells, most of the eNOS is localized at the cell membrane. However, within 5 min following addition of bradykinin, nearly all the eNOS translocates to structures in the cell cytosol; following more protracted incubations with bradykinin, most of the cytosolic enzyme subsequently translocates back to the cell membrane. The bradykinin-induced internalization of eNOS is completely abrogated by the intracellular Ca2+ chelator BAPTA; conversely, Ca2+-mobilizing drugs and agonists promote eNOS translocation. These results establish that eNOS targeting to the membrane is labile and is subject to receptor-regulated Ca2+-dependent reversible translocation, providing another point for regulation of NO-dependent signaling in the vascular endothelium. endothelial nitric-oxide synthase 1,2-bis-(o-aminophenoxy)ethane-N, N, N′,N′-tetraacetic acid tetra(acetoxymethyl) ester bovine aortic endothelial cells. A wide variety of signaling proteins undergo subcellular translocation following their activation. Protein kinases, heterotrimeric G proteins, receptors, phospholipases; all these and many other signaling proteins may migrate from membrane to cytosol, from cytosol to membrane, or from one membrane compartment to another. For one protein, translocation may promote the desensitization of the signaling response; for another, subcellular translocation may be essential to fully activate the cell signaling pathway. These subcellular migrations may be modulated by reversible protein acylations, phosphorylations, protein-protein interactions, or ligand binding. The endothelial isoform of nitric-oxide synthase (eNOS)1 can be modified by all of these processes; eNOS is regulated by both acylation and phosphorylation, and the protein reversibly interacts with disparate other proteins and ligands (for review, see Ref. 1Sase K. Michel T. Trends Cardiovasc. Med. 1997; 7: 28-37Crossref PubMed Scopus (84) Google Scholar). However, data on the role of the subcellular localization of eNOS in the enzyme's dynamic regulation remain controversial. Previous reports have assigned eNOS to the Golgi apparatus (2Sessa W.C. Garcia-Cardena G. Liu J. Keh A. Pollock J.S. Bradley J. Thiru S. Braverman I.M. Desai K.M. J. Biol. Chem. 1995; 270: 17641-17644Abstract Full Text Full Text PDF PubMed Scopus (228) Google Scholar, 3Liu J. Hughes T.E. Sessa W.C. J. Cell Biol. 1997; 137: 1525-1535Crossref PubMed Scopus (158) Google Scholar), yet others have found the enzyme in cell membranes (4Pollock J.S. Nakane M. Buttery L.D. Martinez A. Springall D. Polak J.M. Forstermann U. Murad F. Am. J. Physiol. 1993; 265: C1379-C1387Crossref PubMed Google Scholar, 5Hecker M. Mulsch A. Bassenge E. Forstermann U. Busse R. Biochem. J. 1994; 299: 247-252Crossref PubMed Scopus (118) Google Scholar) or exclusively in plasmalemmal caveolae (6Shaul P.W. Smart E.J. Robinson L.J. German Z. Yuhanna I.S. Ying Y. Anderson R.G.W. Michel T. J. Biol. Chem. 1996; 271: 6518-6522Abstract Full Text Full Text PDF PubMed Scopus (626) Google Scholar, 7Feron O. Belhassen L. Kobzick L. Smith T.W. Kelly R.A. Michel T. J. Biol. Chem. 1996; 271: 22810-22814Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar). Some investigators have failed to observe any agonist-promoted eNOS subcellular translocation (8Liu J. Garcia-Cardena G. Sessa W.C. Biochemistry. 1995; 34: 12333-12340Crossref PubMed Scopus (108) Google Scholar), yet others have used biochemical approaches to suggest that the enzyme's targeting can be dynamically regulated (9Michel T. Li G.K. Busconi L. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 6252-6256Crossref PubMed Scopus (305) Google Scholar, 10Dudek R. Wildhirt S. Suzuki H. Winder S. Bing R.J. Pharmacology. 1995; 50: 257-260Crossref PubMed Scopus (5) Google Scholar, 11Fukuda S.-I. Takaichi S. Naritomi H. Hashimoto N. Nagata I. Nozaki K. Kikuchi H. Brain Res. 1995; 696: 30-36Crossref PubMed Scopus (19) Google Scholar). Using quantitative immunofluorescence imaging techniques, the current studies establish that eNOS is targeted to the cell membrane and that the enzyme's intracellular distribution is dynamically regulated by Ca2+-mobilizing agonists in vascular endothelial cells. eNOS is a Ca2+-calmodulin-dependent enzyme and is transiently activated by increases in intracellular Ca2+elicited by activation of diverse G protein-coupled receptors in endothelial cells and cardiac myocytes. Bradykinin represents one important endogenous activator of eNOS in the vascular wall. In the vascular endothelium, bradykinin binds to and stimulates Ca2+-mobilizing B2 receptors, leading to vasorelaxation and to inhibition of platelet aggregation. eNOS undergoes acylation by the fatty acids myristate and palmitate; these modifications are required to target eNOS to the specialized signal-transducing domains in the plasma membrane termed caveolae. Other signaling proteins directly involved in eNOS regulation are also localized in caveolae, including the B2 bradykinin receptor (12de Weerd W.F.C. Leeb-Lundberg L.M.F. J. Biol. Chem. 1997; 272: 17858-17866Abstract Full Text Full Text PDF PubMed Scopus (235) Google Scholar) and the m2 muscarinic cholinergic receptor in cardiac myocytes. Targeting to caveolae thus appears to facilitate eNOS activation by these Ca2+-coupled signaling pathways. In resting endothelial cells, the eNOS enzyme is tonically inhibited by its protein-protein interactions with caveolin, the resident scaffolding protein in plasmalemmal caveolae. In response to Ca2+-mobilizing agonists, calmodulin both promotes the dissociation of caveolin from eNOS and directly activates the enzyme. Biochemical approaches have also established that prolonged agonist treatment leads to translocation of a proportion of the eNOS protein from particulate to more soluble subcellular fractions, associated with phosphorylation (9Michel T. Li G.K. Busconi L. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 6252-6256Crossref PubMed Scopus (305) Google Scholar) and depalmitoylation (13Robinson L.J. Busconi L. Michel T. J. Biol. Chem. 1995; 270: 995-998Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar) of the enzyme. However, the cell biological correlates of agonist-induced translocation remain obscure, and the biochemical data are controversial. We have therefore explored the regulation of eNOS targeting using cellular imaging approaches and have discovered that the enzyme is reversibly targeted to endothelial cell membranes and that changes in intracellular Ca2+ represent a key determinant for eNOS redistribution. Tissue culture reagents were from Life Technologies, Inc. eNOS monoclonal and caveolin polyclonal antibodies were from Transduction Laboratories. Secondary antibodies (rhodamine- or fluorescein-conjugated goat anti-mouse, rhodamine-conjugated goat anti-rabbit) were from Pierce. Fluo-3/AM was from Molecular Probes (Eugene, OR); BAPTA/AM was from Calbiochem; HOE140 was from Hoechst. Other reagents were from Sigma. Bovine aortic endothelial cells (BAEC) were purchased from Cell Systems and maintained in culture in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, penicillin, and streptomycin (complete medium), as described previously (14Lamas S. Marsden P.M. Li G.K. Tempst P. Michel T. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 6348-6352Crossref PubMed Scopus (920) Google Scholar). Thapsigargin, A23187, and BAPTA/AM were dissolved in Me2SO, and cells were treated with thapsigargin (5 μm final concentration) and A23187 (10 μm) in Hanks' balanced salt solution with or without Ca2+ (1.5 mm) for 5 min at 37 °C. For studying effects of BAPTA, cells were preincubated with BAPTA/AM (20 μm final concentration) in complete medium at 37 °C for 30 min. The stock solution of bradykinin was prepared in phosphate buffered saline (PBS) and used at various final concentrations in complete medium at 37 °C. For cell imaging studies, BAEC were cultured onto gelatin-coated glass coverslips the day before analysis; cells were studied at passage 6. BAEC were fixed in 2% freshly prepared paraformaldehyde for 10 min at room temperature and permeabilized by adding (final concentrations) 0.1% Triton X-100 and 0.1% bovine serum albumin for 5 min at room temperature. The fixed cells were incubated for 1.5 h at room temperature (or overnight at 4 °C) in 10% goat serum and then with monoclonal anti-eNOS antibody at 1:250 dilution for 1 h at room temperature. The cells were then washed three times with PBS and then incubated with rhodamine-conjugated goat anti-mouse antibody at 1:200 dilution for 1 h at room temperature. A similar protocol was followed for the immunostaining of BAEC with Na+/K+-ATPase and caveolin-1 antibodies. Cells were analyzed using a Zeiss epifluorescence microscope equipped with differential interference contrast optics. The cells were imaged at × 100–1000 magnification using a charge-coupled device camera (model CH250, Photometrics Ltd.) cooled to −40 °C. We used conservative criteria to determine the presence of membrane-associated eNOS immunostaining. Since the membrane staining of eNOS was usually nonuniform in each individual cell, a cell was assigned as eNOS membrane-positive if even a small patch of membrane-associated eNOS was detected. Quantitative analyses of cells for the presence of membrane-associated eNOS were performed in a completely blinded fashion, after which the data were collated and normalized to the proportion of cells with membrane-associated eNOS under basal conditions. For each experiment at least 100 cells/coverslip were analyzed. Results are reported as an average of at least four independent blinded experiments performed in duplicate on different days; interexperimental variability was less than 5%. Intracellular calcium determinations with the indicator dye Fluo-3 were performed as described previously (15Kao J.P.Y. Harootunian A.T. Tsien R.Y. J. Biol. Chem. 1989; 264: 8179-8184Abstract Full Text PDF PubMed Google Scholar). A stock solution of Fluo-3/AM, 1 mm in Me2SO was diluted to the final concentration of 10 μm with Hanks' balanced salt solution. One ml of this solution was layered on a coverslip bearing BAEC, and cells were incubated for 60 min at room temperature in the dark. Cells were then washed three times with Hanks' balanced salt solution, sealed onto a custom microscopy chamber, and examined immediately. The chamber was designed to facilitate addition and removal of medium without disturbing the cells. A diamond pencil was used to cut two slivers of equal size from a No. 1 coverslip. The silvers were sealed on a glass slide with nail polish at the two longitudinal edges, creating a channel in the center. Pressure was applied to ensure uniform sealing and leveling of the slivers. The coverslip bearing BAEC was inverted and sealed on the slivers with nail polish, forming a chamber that held approximately 100 μl of medium. The stock solution of bradykinin was diluted to 1 μm(final concentration) with complete medium and used immediately. A 1-ml tuberculin syringe containing bradykinin solution or medium alone was used to exchange at least 300 μl of medium rapidly, ensuring complete medium exchange for each experimental treatment. Epifluorescence microscopy was used to record fluorescence images of cells in real time after bradykinin treatment. Typically, six to eight cells were identified in a field of view (× 250 magnification), and changes in the integrated fluorescence intensity of each cell were monitored over time. Image processing software (Metamorph, Universal Imaging, West Chester, PA) was used to draw cell boundaries and to integrate the fluorescence intensity over all pixels within the boundary of each cell. Calcium measurements were not affected by the exchange of drug-free medium alone. Immunostaining of BAEC using monoclonal eNOS antibody revealed a robust pattern of immunofluorescence (Fig. 1); when nonimmune mouse IgG1 was used as the primary antibody in identically processed samples, there was no staining (not shown). The cellular distribution of eNOS and caveolin immunoreactivity exhibited considerable heterogeneity. The majority of untreated endothelial cells (∼60–80%) showed prominent eNOS immunostaining at the cell periphery; the remaining 20–40% of cells had no evident staining at the cell edge and showed eNOS distributed only in a patchy intracellular pattern with enhanced perinuclear staining (Fig. 1 A). This patchy pattern of immunofluorescence has been observed for other caveolae-targeted proteins such as caveolin, cationic amino acid transporter protein, and c-Src, as well as prototypical “plasma membrane” receptors such as the cholecystokinin receptor and the high density lipoprotein receptor SR-B1 (16Smart E.J. Ying Y.-S. Conard P.A. Anderson R.G.W. J. Cell Biol. 1994; 127: 1185-1197Crossref PubMed Scopus (377) Google Scholar, 17McDonald K.K. Zharikov S. Block E.R. Kilberg M.S. J. Biol. Chem. 1997; 272: 31213-31216Abstract Full Text Full Text PDF PubMed Scopus (401) Google Scholar, 18Babitt J. Trigatti B. Rigotti A. Smart E.J. Anderson R.G.W. Xu S. Krieger M. J. Biol Chem. 1998; 272: 13242-13249Abstract Full Text Full Text PDF Scopus (337) Google Scholar, 19Li S. Couet J. Lisanti M.P. J. Biol. Chem. 1996; 271: 29182-29190Abstract Full Text Full Text PDF PubMed Scopus (674) Google Scholar, 20Roettger B. Rentsch R.U. Pinon D. Holicky E. Hadac E. Larkin J.M. Miller L.J. J. Cell Biol. 1995; 128: 1029-1041Crossref PubMed Scopus (204) Google Scholar). The precise identity of the intracellular sites at which these proteins localize remains less well understood. As shown in Fig. 1 C, caveolin and eNOS shared a similar but incompletely overlapping pattern of distribution in endothelial cells, with staining for the two proteins seen both at the plasma membrane and in similar intracellular locales. The proportion of untreated cells without detectable eNOS at the membrane was variable from experiment to experiment (range 20–40%), but was quite consistent under identical experimental conditions within duplicate analyses. This heterogeneous pattern of membrane staining suggested that eNOS targeting may be influenced by cellular processes not definitively controlled in these experiments. Quantitative analyses of endothelial cells with any membrane-associated eNOS showed that ∼70% of the cells' total immunoreactivity was present at the plasma membrane. Even within the positively staining endothelial cells, the membrane distribution of eNOS was usually nonuniform, and there were often large patches of eNOS-positive membrane located immediately adjacent to eNOS-negative regions (see Fig. 1). Importantly, when endothelial cells were treated with bradykinin (1 μm, 5 min), the pattern of eNOS immunostaining markedly changed (Fig. 1 B); compared with untreated cells (Fig. 1 A), BAEC treated with bradykinin showed a dramatic redistribution of eNOS from the cell membrane to a distinct ring pattern around the cell nucleus. Using similar immunofluorescence techniques, we found (data not shown) that the cellular distribution of other membrane-associated proteins (Na+/K+-ATPase; caveolin) exhibited no cellular redistribution following bradykinin treatment. The next series of experiments sought to validate the pharmacological characteristics of the bradykinin-induced eNOS redistribution. Given the heterogeneity of eNOS immunostaining within and between BAEC, we devised a conservative criterion for assessing whether eNOS translocation from the membrane had taken place. Endothelial cells showing any identifiable membrane-associated eNOS immunostaining were scored as “membrane-positive”; only those cells completely devoid of membrane-associated eNOS were scored as negative. All samples were coded to permit the analyses to be performed and quantitated by an blinded observer unaware of the experimental treatment of the samples. Each experiment was performed in duplicate and repeated at least four times on different days using independently cultured cells. Because the proportion of cells scored as eNOS membrane-positive under basal conditions ranged from ∼60% to more than 80%, for each experiment results were normalized to the measured basal value on that day. For the analyses performed on any given day, duplicate values were reproducible within each experimental treatment; the percentage of cells positive for eNOS membrane targeting for any particular treatment varied by <5% between duplicate samples. Having validated the reproducibility and robustness of this experimental approach, we performed a dose-response analysis for bradykinin induced redistribution of eNOS (Fig. 2). After treating BAEC for 5 min with varying concentrations of bradykinin, the cells were fixed and immunostained, and the proportion of cells with membrane-associated eNOS were quantitated. The EC50 for promotion of eNOS translocation by bradykinin was 1 nm; the maximum effect was observed at 1 μm bradykinin. The B2-receptor antagonist HOE140 completely blocked bradykinin-induced eNOS redistribution; HOE140 alone did not affect eNOS distribution (data not shown). The time courses of bradykinin-stimulated redistribution of eNOS and of bradykinin-stimulated changes in intracellular Ca2+concentration are shown in Fig. 3,A and B, respectively. For immunofluorescence experiments, BAEC were treated with 1 μM bradykinin for varying times, then fixed and processed as described above. For measurements of intracellular Ca2+ concentration, BAEC were first incubated with the indicator dye Fluo-3 for 60 min, then exposed to bradykinin (1 μm) while determining the fluorescence emission of intracellular Fluo-3 at varying times. Treatment of endothelial cells with bradykinin resulted in a rapid loss of eNOS protein from the membrane; within 5 min, only 10 ± 4% of the BAEC originally showing eNOS membrane staining remained positive (n = 25). Upon prolonged incubation with bradykinin, the proportion of eNOS at the membrane gradually recovered; 60 min following addition of bradykinin, the proportion of cells with positive eNOS membrane staining reached 82 ± 8% of the value seen before the addition of drug (n = 4). The time course of the bradykinin-induced increase in intracellular calcium concentration ([Ca2+]i) followed a similar but not identical time course (Fig. 3 B). There was a rapid initial rise of [Ca2+]i nearly to maximal values within 1 min following the addition of bradykinin, followed by a slower increase of [Ca2+]i over the next 20 min. The bradykinin-induced increase in [Ca2+]i began to return to base line after 30 min following addition of bradykinin, associated with the recovery of membrane-associated eNOS. The similar temporal patterns of bradykinin-induced changes in [Ca2+]i and eNOS distribution led us to conduct a series of experiments to investigate further whether eNOS translocation might be mediated by changes in intracellular Ca2+. In the presence of extracellular Ca2+, the calcium ionophore A23187 promoted a rapid translocation of eNOS from the membrane (Fig. 4 A). However, when A23187 was added to BAEC in the absence of extracellular Ca2+, there was a significant and reproducible increase in the proportion of cells scored positive for eNOS membrane association. Presumably, this reflected the depletion of intracellular Ca2+ stores by the equilibration between intracellular Ca2+ and a large volume of extracellular Ca2+-free medium. This interpretation was consistent with the effects of treating BAEC with thapsigargin, a specific inhibitor of the endoplasmic reticulum Ca2+-ATPase, which is known to increase [Ca2+]i. As shown in Fig. 4 A, addition of thapsigargin to endothelial cells promoted eNOS translocation from the membrane. In contrast, when BAEC were treated with A23187 plus thapsigargin in Ca2+-free medium, there was an increase in the proportion of cells with membrane-targeted eNOS. These results indicate that the [Ca2+]i plays a crucial role in the membrane targeting of eNOS. Bradykinin B2 receptors are coupled through G proteins to the activation of phospholipases C and A2 (21Mombouli J.-V. Vanhoutte P.M. Annu. Rev. Pharmacol. Toxicol. 1995; 35: 679-705Crossref PubMed Scopus (200) Google Scholar), leading to the transient increases in [Ca2+]i characteristic of the physiological response to bradykinin (22Adams D.J. Barakeh J. Laskey R. Van Breeman C. FASEB J. 1989; 3: 2389-2400Crossref PubMed Scopus (376) Google Scholar). The influence of intracellular Ca2+ on eNOS translocation was explored further using the intracellular Ca2+ chelator BAPTA. As shown in Fig. 4 B, preincubation of endothelial cells with BAPTA completely blocked bradykinin-induced eNOS redistribution. Our results thus suggest that increases in [Ca2+]imay be both necessary and sufficient for eNOS translocation. It has been shown previously (23Isshiki M. Ando J. Korenaga R. Kogo H. Fujimoto T. Kamiya A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 5009-5014Crossref PubMed Scopus (128) Google Scholar) that receptor-activated increases in intracellular calcium arise from regions of the endothelial cell membrane enriched in caveolin and quickly lead to increases in [Ca2+]i throughout the cell. The nonuniform distribution of eNOS and caveolin along the endothelial cell membrane (Fig. 1) is reminiscent of the patchy membrane distribution described for caveolin (16Smart E.J. Ying Y.-S. Conard P.A. Anderson R.G.W. J. Cell Biol. 1994; 127: 1185-1197Crossref PubMed Scopus (377) Google Scholar, 23Isshiki M. Ando J. Korenaga R. Kogo H. Fujimoto T. Kamiya A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 5009-5014Crossref PubMed Scopus (128) Google Scholar) and shown to correlate with regions of localized Ca2+-dependent signaling. The dynamic equilibrium of eNOS membrane targeting in cultured endothelial cells is thus exquisitely sensitive to changes in intracellular calcium concentration. The heterogeneity of eNOS immunostaining, and its lability in the face of diverse agonists and under different conditions, may also help to explain the discordance of our observations with several earlier reports. For example, Sessaet al. (2Sessa W.C. Garcia-Cardena G. Liu J. Keh A. Pollock J.S. Bradley J. Thiru S. Braverman I.M. Desai K.M. J. Biol. Chem. 1995; 270: 17641-17644Abstract Full Text Full Text PDF PubMed Scopus (228) Google Scholar) and Liu et al. (3Liu J. Hughes T.E. Sessa W.C. J. Cell Biol. 1997; 137: 1525-1535Crossref PubMed Scopus (158) Google Scholar) failed to see any membrane-associated eNOS using immunofluorescence methods similar to those used in the current report; Venema et al. (24Venema V.J. Marrero M.B. Venema R.C. Biochem. Biophys. Res Commun. 1996; 226: 703-710Crossref PubMed Scopus (98) Google Scholar) visualized a small fraction of eNOS protein in endothelial membranes. The utilization of different antibodies and disparate culture conditions, the possibility of aberrant protein targeting in heterologous expression systems, untoward effects of growing cells in serum-free media; these may represent some of the confounding factors that could explain the negative findings of these earlier reports. These studies also reveal a discrimination in the analysis of eNOS subcellular targeting as revealed by cellular imaging compared with biochemical approaches. When lysed endothelial cells are resolved into soluble and particulate preparations by ultracentrifugation, nearly all the eNOS enzyme is recovered in the particulate fraction. However, the particulate subcellular fraction, as simplistically defined by differential ultracentrifugation, has a heterogeneous composition. In the case of eNOS, the enzyme's targeting to the particulate fraction in resting endothelial cells reflects its association with intracellular membranes as well as cell surface structures. Following bradykinin treatment, essentially all the eNOS immunoreactivity is found around the circumference of the nucleus, possibly apposed to the nuclear membrane, raising interesting speculations about possible nuclear targets for NO following eNOS translocation. The most plausible physiological consequence of eNOS redistribution following agonist activation is the enzyme's sequestration away from its proximal activators and concomitant attenuation of the extracellular release of NO. The time course of eNOS activation is much more rapid than the time course of enzyme translocation in the endothelial cell. Using a selective NO electrode, Malinski and Taha (25Malinski T. Taha Z. Nature. 1992; 358: 676-678Crossref PubMed Scopus (1029) Google Scholar) found that bradykinin activates NO synthesis in endothelial cells within seconds of drug addition, with enzyme activity returning to base line in ∼5 min. In contrast, bradykinin-induced translocation of eNOS is maximum only at 5 min and persists for several tens of minutes until the enzyme returns to the membrane (Fig. 3). These observations suggest that the activation and translocation processes reflect distinct components of the bradykinin response, with translocation plausibly representing a mechanism to down-regulate or uncouple enzyme activation from receptor occupancy. Taken together, our results establish that eNOS targeting to the cell membrane is labile and subject to receptor-regulated Ca2+-dependent reversible translocation, thereby providing another point for regulation of NO-dependent signaling in the vascular endothelium. We thank Peter Marks for expert assistance using the Bio-Rad microscope." @default.
• W2012430170 created "2016-06-24" @default.
• W2012430170 creator A5001024082 @default.
• W2012430170 creator A5001662876 @default.
• W2012430170 creator A5031474465 @default.
• W2012430170 creator A5048907425 @default.
• W2012430170 creator A5066047353 @default.
• W2012430170 creator A5084285813 @default.
• W2012430170 date "1998-10-01" @default.
• W2012430170 modified "2023-09-29" @default.
• W2012430170 title "Receptor-regulated Translocation of Endothelial Nitric-oxide Synthase" @default.
• W2012430170 cites W1529590189 @default.
• W2012430170 cites W1965039067 @default.
• W2012430170 cites W1988793690 @default.
• W2012430170 cites W1999087883 @default.
• W2012430170 cites W1999565215 @default.
• W2012430170 cites W2008592533 @default.
• W2012430170 cites W2010100459 @default.
• W2012430170 cites W2020471821 @default.
• W2012430170 cites W2028880044 @default.
• W2012430170 cites W2042695353 @default.
• W2012430170 cites W2044918962 @default.
• W2012430170 cites W2068804833 @default.
• W2012430170 cites W2070999822 @default.
• W2012430170 cites W2071756355 @default.
• W2012430170 cites W2076490603 @default.
• W2012430170 cites W2084379296 @default.
• W2012430170 cites W2095480781 @default.
• W2012430170 cites W2098963490 @default.
• W2012430170 cites W2112465136 @default.
• W2012430170 cites W2113354135 @default.
• W2012430170 cites W2158709030 @default.
• W2012430170 cites W2175687760 @default.
• W2012430170 cites W38526789 @default.
• W2012430170 cites W83466104 @default.
• W2012430170 cites W2081686903 @default.
• W2012430170 doi "https://doi.org/10.1074/jbc.273.42.27383" @default.
• W2012430170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9765266" @default.
• W2012430170 hasPublicationYear "1998" @default.
• W2012430170 type Work @default.
• W2012430170 sameAs 2012430170 @default.
• W2012430170 citedByCount "152" @default.
• W2012430170 countsByYear W20124301702012 @default.
• W2012430170 countsByYear W20124301702013 @default.
• W2012430170 countsByYear W20124301702014 @default.
• W2012430170 countsByYear W20124301702015 @default.
• W2012430170 countsByYear W20124301702017 @default.
• W2012430170 countsByYear W20124301702019 @default.
• W2012430170 countsByYear W20124301702021 @default.
• W2012430170 countsByYear W20124301702023 @default.
• W2012430170 crossrefType "journal-article" @default.
• W2012430170 hasAuthorship W2012430170A5001024082 @default.
• W2012430170 hasAuthorship W2012430170A5001662876 @default.
• W2012430170 hasAuthorship W2012430170A5031474465 @default.
• W2012430170 hasAuthorship W2012430170A5048907425 @default.
• W2012430170 hasAuthorship W2012430170A5066047353 @default.
• W2012430170 hasAuthorship W2012430170A5084285813 @default.
• W2012430170 hasBestOaLocation W20124301701 @default.
• W2012430170 hasConcept C104317684 @default.
• W2012430170 hasConcept C112243037 @default.
• W2012430170 hasConcept C138626823 @default.
• W2012430170 hasConcept C170493617 @default.
• W2012430170 hasConcept C178790620 @default.
• W2012430170 hasConcept C181199279 @default.
• W2012430170 hasConcept C185592680 @default.
• W2012430170 hasConcept C2777622882 @default.
• W2012430170 hasConcept C2778326061 @default.
• W2012430170 hasConcept C2992676626 @default.
• W2012430170 hasConcept C519581460 @default.
• W2012430170 hasConcept C55493867 @default.
• W2012430170 hasConcept C86803240 @default.
• W2012430170 hasConcept C95444343 @default.
• W2012430170 hasConcept C98274493 @default.
• W2012430170 hasConceptScore W2012430170C104317684 @default.
• W2012430170 hasConceptScore W2012430170C112243037 @default.
• W2012430170 hasConceptScore W2012430170C138626823 @default.
• W2012430170 hasConceptScore W2012430170C170493617 @default.
• W2012430170 hasConceptScore W2012430170C178790620 @default.
• W2012430170 hasConceptScore W2012430170C181199279 @default.
• W2012430170 hasConceptScore W2012430170C185592680 @default.
• W2012430170 hasConceptScore W2012430170C2777622882 @default.
• W2012430170 hasConceptScore W2012430170C2778326061 @default.
• W2012430170 hasConceptScore W2012430170C2992676626 @default.
• W2012430170 hasConceptScore W2012430170C519581460 @default.
• W2012430170 hasConceptScore W2012430170C55493867 @default.
• W2012430170 hasConceptScore W2012430170C86803240 @default.
• W2012430170 hasConceptScore W2012430170C95444343 @default.
• W2012430170 hasConceptScore W2012430170C98274493 @default.
• W2012430170 hasIssue "42" @default.
• W2012430170 hasLocation W20124301701 @default.
• W2012430170 hasOpenAccess W2012430170 @default.
• W2012430170 hasPrimaryLocation W20124301701 @default.
• W2012430170 hasRelatedWork W1971814334 @default.
• W2012430170 hasRelatedWork W1990842025 @default.
• W2012430170 hasRelatedWork W1991996044 @default.
• W2012430170 hasRelatedWork W2074424222 @default.
• W2012430170 hasRelatedWork W2374639172 @default.
• W2012430170 hasRelatedWork W2388905353 @default.

• next